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Obesity in youth increases the risk of type 2 diabetes (T2D), and both are risk factors for neurocognitive deﬁcits. Exercise attenuates
the risk of obesity and T2D while improving cognitive function. In adults, these beneﬁts are associated with the actions of the
brain-derived neurotrophic factor (BDNF), a protein critical in modulating neuroplasticity, glucose regulation, fat oxidation, and
appetite regulation in adults. However, little research exists in youth. This study examined the associations between changes in
diabetes risk factors and changes in BDNF levels after 6 months of exercise training in adolescents with obesity. The sample
consisted of 202 postpubertal adolescents with obesity (70% females) aged 14–18 years who were randomized to 6 months of
aerobic and/or resistance training or nonexercise control. All participants received a healthy eating plan designed to induce a
250/kcal deﬁcit per day. Resting serum BDNF levels and diabetes risk factors, such as fasting glucose, insulin, homeostasis
model assessment (HOMA-B—beta cell insulin secretory capacity) and (HOMA-IS—insulin sensitivity), and hemoglobin A1c
(HbA1c), were measured after an overnight fast at baseline and 6 months. There were no signiﬁcant intergroup diﬀerences on
changes in BDNF or diabetes risk factors. In the exercise group, increases in BDNF were associated with reductions in fasting
glucose (β=−6.57, SE= 3.37, p = 0 05) and increases in HOMA-B (β= 0.093, SE= 0.03, p = 0 004) after controlling for
confounders. No associations were found between changes in diabetes risk factors and BDNF in controls. In conclusion,
exercise-induced reductions in some diabetes risk factors were associated with increases in BDNF in adolescents with obesity,
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suggesting that exercise training may be an eﬀective strategy to promote metabolic health and increases in BDNF, a protein
favoring neuroplasticity. This trial is registered with ClinicalTrials.gov NCT00195858, September 12, 2005 (funded by the
Canadian Institutes of Health Research).
1. Introduction
Pediatric obesity currently aﬀects 13–20% of children and
youth in Westernized countries [1, 2]. Obesity is associated
with a myriad of deleterious health outcomes, including
diminished neurocognitive function in childhood [3], an
increased risk of Alzheimer’s disease, and dementia later in
life [4], possibly due to increased inﬂammatory cytokines
which have systemic eﬀects linked to glycemic dysregulation
and the initiation of type 2 diabetes (T2D) pathology [5]. Obe-
sity is well known to increase the risk of T2D [6], and T2D in
adulthood is one of the strongest independent risk factors for
neurological disease [7, 8]. In children and youth, recurrent
hyperglycemia is associated with adverse structural brain
outcomes, including reduced gray and white matters [9],
suggesting that improving metabolic regulation early in life is
important for long-termbrain health.Althoughpoorly under-
stood, the proposed mechanisms contributing to increased
risk of neurocognitive dysfunction with these conditions
include poor glycemic regulation [10] and alterations in the
brain-derived neurotrophic factor (BDNF) [11].
BDNF is a member of the neurotrophin family of pro-
teins and is chieﬂy recognized for its role in facilitating
aspects of neural plasticity and long-term potentiation [12].
In addition to its neurogenic eﬀects, BDNF also exerts
metabotropic eﬀects, including the regulation of whole-
body energy homeostasis and feeding behavior [11], skeletal
muscle fat oxidation [13], beta cell functioning [14], and
hepatic glycemic control [14]. BDNF crosses the blood-
brain barrier in a bidirectional manner [15], and circulating
levels reﬂect cortical BDNF [16, 17]. Low circulating BDNF
is associated with both neurological and metabolic condi-
tions including, major depressive disorder [18], Alzheimer’s
disease [19], obesity [20, 21], and T2D [22]. In fact, adults
with obesity and adults with T2D have signiﬁcantly lower
circulating BDNF compared to lean, nondiabetic adults, pos-
sibly owing to hyperglycemia-induced reductions in plasma
BDNF [22]. It has recently been suggested that BDNF may
play an etiological role in obesity and metabolic syndrome
via in utero “developmental programming” of the obesity
and T2D phenotypes [23]. Indeed, BDNF-haploinsuﬃcient
mice are obese and diabetic and exhibit hyperphagic
behavior [24], and expression of the BDNF gene variant
(Val66Met) is signiﬁcantly associated with measures of
obesity in human pediatric [20] and adult cohorts [21].
Interestingly, increasing BDNF levels improves meta-
bolic regulation, as intracerebroventricular infusion of exog-
enous BDNF suppresses appetite [24, 25] and improves
systemic glycemic control via hepatocyte insulin sensitivity
[26], pancreatic beta cell function [14, 27], and increased
glucose utilization [28] in animal models. Further, overex-
pression of hypothalamic BDNF in mice facilitates the brow-
ning of adipose tissue via sympathetic nerve activity, leading
to increased energy expenditure and reduced plasma glucose
levels [29, 30]. Collectively, these ﬁndings demonstrate the
important role of BDNF in metabolic regulation. Therefore,
interventions that increase BDNF expression may have
favorable eﬀects on metabolic function while improving
neurocognitive outcomes in youth with obesity and/or
T2D [23, 31].
Exercise training is one intervention strategy that could
both target BDNF and improve metabolic function. Exercise
plays an important role in the management of pediatric obe-
sity [32] and its metabolic comorbidities [33] and is also
a potent tool for increasing circulating levels of BDNF
[34, 35]. Acute bouts of moderate-to-vigorous intensity aero-
bic exercise consistently increase circulating BDNF in adults
[35], and aerobic exercise training of at least two weeks in
duration generally, but not universally, increases resting
BDNF levels in adults [34, 36]. Jeon and Ha [37] found that
12 weeks of high-intensity aerobic training increases resting
serum BDNF in healthy adolescent males, which corre-
sponded with neurocognitive (working memory) improve-
ments. Lee et al. [38] observed a 2.5-fold increase in resting
serum BDNF and ~6% reduction in adiposity following 12
weeks of moderate-intensity aerobic training in adolescents
with obesity, whereas these changes were not observed in
those with T2D or in healthy-weight controls. Although these
ﬁndings suggest that exercisemay disproportionately increase
BDNF in youthwith obesity compared to youthwith T2D, the
small sample size (n = 26 overall), the high variability in the
BDNF measures, and the sample composition of only males
warrant caution in drawing conclusions from this work.
Moreover, no indicators of glucose regulation were reported,
thus precluding an evaluation of how changes in BDNF relate
to changes in diabetes risk in the adolescents with obesity.
Given the involvement of BDNF in metabolic regulation
and the ability of exercise to increase BDNF and to improve
body composition and metabolic outcomes, it stands to rea-
son that changes in diabetes risk factors and adiposity may
be related to changes in BDNF following an exercise inter-
vention in youth with obesity. However, no study to date
has investigated these relationships in this population. The
primary aim of this study was to quantify the independent
contribution that demographic, anthropometric, and meta-
bolic indicators make toward the prediction of change in
serum BDNF levels after a 6-month exercise intervention
among a high-risk population of adolescents with obesity.
Given the mechanistic evidence from animal models, we
hypothesized that changes in metabolic indicators including
adiposity, circulating glucose and insulin, insulin sensitivity
and beta cell function, and hemoglobin A1c (HbA1c) would
be associated with changes in BDNF levels from exercise
training. This study represents secondary data analysis from
the healthy eating, aerobic, and resistance training in youth
(HEARTY) trial [39].
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2. Materials and Methods
2.1. Participants. For this secondary analytic study, we only
obtained baseline and postintervention data on resting serum
BDNF and diabetes risk factors on 202 of the 304 participants
who entered the study, due to availability of blood samples.
The sample breakdown for the present study included those
who received exercise interventions (n = 152) or diet-only
controls (n = 50). Participants included 66 boys and 136 girls
aged 14–18 years (15.4 yrs± 1.4), who volunteered for the
HEARTY trial conducted in Ottawa, Canada.
2.1.1. Recruitment. Inclusion criteria were inactive postpu-
bertal (Tanner stages IV–V) adolescents aged 14–18 years
with BMI> 95th percentile for age/sex or ≥85th percentile
for age/sex with an additional diabetes or cardiovascular dis-
ease risk factor as described elsewhere [40]. Exclusion criteria
were any regular physical activity (more than twice a week for
more than 20-minute sessions) four months prior, diagnosis
of T2D, use of any performance enhancing medication, sig-
niﬁcant weight change (increase or decrease of ≥5% during
the two months before enrollment), pregnancy at the start
of the study or intention to become pregnant in the next year,
and any contraindications to activity due to disease or other
illness (eating disorders/clinical depression) judged by the
participant or study physician to make participation inadvis-
able. A parent or guardian was asked to cosign the consent
form of any participant below the age of 16 years. This study
received approval from the Research Ethics Boards at the
Children’s Hospital of Eastern Ontario (protocol #05/04E)
and the Ottawa Hospital Research Institute (protocol
#2004219-01H). The trial began in March 2005 and was
completed in June 2011.
2.2. Design and Procedures. This study represents a secondary
analysis from an exercise intervention that evaluated the
eﬀects of exercise modality on body composition [40]. After
completing baseline testing, participants entered a run-in
period including supervised exercise training four times
weekly for four weeks, whereby participants engaged in
low-intensity, low-volume resistance, and aerobic training.
To qualify for randomization, participants needed to attend
at least 13 of 16 prescribed exercise sessions (>80% adher-
ence) during this run-in phase. Participants (n = 202) were
randomized to exercise or control groups using central
randomization. Participants in the exercise groups were
asked to attend gyms 4 times weekly, following exercise pro-
grams as previously described protocols [39, 40]. Outcome
assessors were blinded to group assignment, ensuring
unbiased measurement. As well, all participants received
counseling by a registered dietitian that was designed to pro-
mote healthy eating with a daily energy deﬁcit of 250 kcal.
(see [40], for complete methodological details concerning
the HEARTY trial).
2.3. Measurements
2.3.1. Demographic and Anthropometric Variables. At base-
line, background information was obtained from all partici-
pants, including demographics (age, race, ethnicity, and
parental education), self-reported pubertal status, measured
height and weight for body mass index (BMI), self-reported
physical activity, family medical history, and current medical
status and medications to evaluate inclusion criteria. BMI
was calculated as weight in kilograms divided by height in
meters squared. At baseline and 6 months, height and weight
were recorded with a manual stadiometer and scale, respec-
tively, with participants wearing light clothing and no shoes.
Body composition was assessed by magnetic resonance
imaging (MRI) (Echospeed, signal 11 version; GE Medical
Systems) at baseline and 6 months. Percent body fat was
analyzed using SliceOMatic™ software V.4.3 (TomoVision,
Magog, Canada).
2.3.2. Diabetes Risk Factors and BDNF. Twelve-hour (over-
night-fasting) samples of approximately 20mL of venous
blood were taken in the morning, from a forearm or antecu-
bital vein, and were stored in a freezer at −80°C. Samples
were obtained at baseline before the run-in period and at
least 48 hours after the last exercise session at the end of
the 6-month intervention to avoid potentially confounding
acute eﬀects of exercise. Samples were analyzed for serum
BDNF and metabolic indicators, including fasting glucose
(mmol/L), fasting insulin (mmol/L), and HbA1c (percent-
age) as reported by Alberga et al. [40]. The homeostasis
model assessment (HOMA) was used to assess beta cell insu-
lin secretory capacity (HOMA-B) and insulin sensitivity
(HOMA-IS) using the computer program and equations cal-
culated by Wallace et al. [41] and Levy et al. [42]. HOMA
assesses insulin secretory capacity and insulin resistance
based on fasting glucose and insulin concentrations from
blood samples drawn at the same time. The model is based
on data from physiological studies and has been validated
against other methods of assessing insulin secretory capacity
and insulin [41, 42]. Importantly, HOMA can be used to lon-
gitudinally track changes in insulin sensitivity and beta cell
function following an exercise intervention [41]. A free,
online calculator provided courtesy of the University of
Oxford was used to calculate HOMA using HOMA model
2 (https://www.dtu.ox.ac.uk/homacalculator) [41].
BDNF was analyzed using a commercially available
ELISA kit (Human Free BDNF Quantikine ELISA kit, R&D
Systems, Cat# DBD00) in accordance with the manufac-
turer’s instructions. Serum samples of BDNF were diluted
75-fold into Calibrator Diluent RD6P prior to starting the
assay, and all samples were run in duplicate. The sensitiv-
ity of this assay product is 20 pg/mL with a range of
62.5–4000 pg/mL. All standard curves were linear within
the range used for the analysis with a strong correspond-
ing correlation of coeﬃcient (r2 > 0.99).
2.4. Statistical Analysis. Baseline demographics were summa-
rized as means and standard deviations, and between group
diﬀerences were examined using a one-way analyses of vari-
ance for continuous data. Categorical data were summarized
as frequencies and percentages, and group diﬀerences at
baseline were examined using chi-square tests. Spearman
correlations were performed to determine the unadjusted
association between changes in body composition, metabolic
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risk factors, and changes in BDNF levels. We previously ran
linear mixed-eﬀects regression modeling for repeated mea-
sures to assess the eﬀects of exercise training on changes in
resting serum BDNF over time, with BDNF as the dependent
variable, group (aerobic, resistance, combined, and control),
time (baseline and 6 months), and group× time interaction
as the independent variables, with adjustment for age and
sex using an unstructured covariance matrix for the repeated
measures [43]. Results from these mixed-model regressions
and Spearman correlations showed that changes in BDNF
levels did not diﬀer signiﬁcantly by the exercise group [43],
and the pattern of association between changes in body com-
position, metabolic markers, and BDNF was comparable
across exercise groups (data not reported). Thus, a combined
analytic approach was used whereby all exercise groups were
pooled to form one group. Multiple linear regression models
were then conducted to identify the independent prediction
of changes in BDNF (dependent variable) from changes in
anthropometrics and all metabolic indicators. Given that
anthropometric variables were colinear, only BMI was used
in the regression models to make results comparable to exist-
ing anthropometry literature. Moreover, the patterns of
association remained the same when other indicators of
anthropometry, such as percent body fat and waist circum-
ference, were used. All regression analyses were adjusted
for age, gender, and highest level of parent education as a
proxy for sociodemographic status. Data are presented as
standardized beta weights and standard errors (SEs). Statisti-
cal signiﬁcance was deﬁned as a two-tailed p < 0 05. Analyses
were conducted using SAS, version 9.4 (SAS Institute, Cary,
North Carolina).
3. Results
Table 1 shows baseline characteristics of the sample. Most
participants (182 of 202 or 90%) had obesity (BMI≥ 95th
percentile for age and sex). The sample was about 70%
Caucasian, and most parents had some postsecondary educa-
tion. There were no statistically signiﬁcant group diﬀerences
on sociodemographic variables, body composition, BDNF
levels, or diabetes risk factors.
In the main outcome analysis, there was no signiﬁ-
cant group× time interaction for BDNF (F 3, 227 = 0 89,
p = 0 45), indicating that changes between groups over time
did not diﬀer signiﬁcantly as reported elsewhere [43]. Simi-
larly, there were no group diﬀerences in changes in diabetes
risk factors from exercise intervention, as reported elsewhere
[39]. Gender did not moderate the eﬀects of exercise training
on changes in BDNF or diabetes risk factors, as reported
elsewhere [39, 43].
There were no signiﬁcant associations at baseline
between BDNF levels and age (r =−0.02, p = 0 79), gender
(r = 0 07, p = 0 37), highest parent education (r = 0 02,
p = 0 77), BMI (r =−0.08, p = 0 33), waist circumference
(r = 0 033, p = 0 68), or percent body fat (r = 0 00, p = 0 99).
Table 2 presents the unadjusted correlations between
changes in anthropometrics and diabetes risk factors after 6
months of exercise intervention for all exercise groups
combined and controls. As expected, for diet-only controls,
no signiﬁcant correlations emerged between changes in
BDNF and changes in fasting glucose (r =−0.018, p = 0 90),
fasting insulin (r =−0.043, p = 0 77), HbA1c (r =−0.015,
p = 0 92), HOMA-B (r =−0.056, p = 0 71), and HOMA-IS
(r = 0 06, p = 0 67). In the exercise group, however, unad-
justed increases in BDNF were associated with reductions
in fasting glucose (r =−0.17, p = 0 04) and increases in
HOMA-B (r = 0 23, p = 0 005). No signiﬁcant associations
emerged for changes in BDNF and changes in fasting insulin,
HbA1c, and HOMA-IS or anthropometrics when all exer-
cise groups were combined.
Table 3 presents the associations between changes in
metabolic indicators and anthropometrics and changes in
BDNF levels, controlling for age, gender, and highest level
of parent education. The associations between 6-month
changes in BDNF and changes in fasting glucose (β=6.57,
SE=3.37, p = 0 05) and HOMA-B (β=0.093, SE=0.03,
p = 0 004) in the exercise group remained statistically signif-
icant after adjusting for confounders.
Table 1: Participant characteristics at baseline.
Total sample
(n = 202)
Exercise
(n = 152)
Control
(n = 50)
Males, N (%) 66 (32.7) 50 (32.9) 16 (32)
Females, N (%) 136 (67.3) 102 (67.1) 34 (68)
Age (years) 15.5 (1.4) 15.5 (1.4) 15.4 (1.3)
Weight (kg) 97.8 (17.1) 97.9 (16.7) 97.5 (18.3)
Height (cm) 168.1 (7.6) 168.0 (7.7) 168.3 (7.1)
BMI (m/kg2) 34.5 (4.4) 34.5 (4.1) 34.3 (5.1)
Percent body fat 49.1 (5.4) 49.3 (5.3) 48.5 (5.6)
Waist circumference (cm) 96.7 (10.6) 97.1 (10.3) 95.3 (11.2)
BDNF 26 (14.2) 26.2 (14.3) 25.2 (14)
Glucose 5 (0.4) 5.0 (0.4) 5.1 (0.4)
Insulin 103.6 (58) 99.4 (52.0) 116.4 (72.5)
HOMA %B 145.5 (50.4) 144.6 (50.6) 148.5 (50.3)
HOMA %IS 65.9 (30.3) 67.9 (31.3) 59.8 (26.5)
HbA1c (%) 5.0 (0.3) 5.0 (0.3) 5.0 (0.2)
Ethnicity, N (%)
Caucasian 149 (73.8) 107 (70.4) 42 (84.0)
Black 14 (6.9) 12 (7.9) 2 (4.0)
Mixed racial 7 (3.5) 6 (3.9) 1 (2.0)
Arabic 8 (4.0) 7 (4.6) 1 (2.0)
Hispanic 9 (4.5) 9 (5.9) 0 (0.0)
Asian 6 (3.0) 5 (3.3) 1 (2.0)
Other 4 (2.0) 3 (2.0) 1 (2.0)
Native Canadian 4 (2.0) 2 (1.3) 2 (4.0)
Indonesian/Asian 1 (0.5) 1 (0.7) 0 (0.0)
Highest parental
education, N (%)
High school or less 30 (14.9) 22 (14.5) 8 (16.0)
College/university 172 (85.1) 130 (85.5) 42 (84.0)
Note: BMI = body mass index; BDNF = brain-derived neurotrophic factor;
HbA1c = hemoglobin A1c; HOMA-B = homeostatic model assessment beta
cell secretory capacity; HOMA-IS = homeostatic model assessment insulin
sensitivity.
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4. Discussion
This study investigated the independent associations
between changes in serum BDNF, diabetes risk factors, and
body composition following a 6-month exercise intervention
in adolescents with obesity. The main ﬁndings from this
study were (a) changes in some diabetes risk factors, most
notably fasting glucose and beta cell insulin secretory capac-
ity (HOMA-B), were stronger independent predictors of
exercise-induced changes in BDNF than changes in body
composition and (b) there was no relationship between
anthropometric variables and BDNF at baseline or following
the 6-month intervention period.
In animal models, the relationship between obesity and
BDNF is quite robust and consistent [23, 30]. The arcuate
nucleus of the hypothalamus (ARC) regulates feeding behav-
ior and long-term energy stores of the body (i.e., adiposity)
via leptin signaling and glucose sensing [30]. BDNF is
thought to mediate neural plasticity in ARC pathways in
response to energetic challenges (fasting, caloric restriction)
and physical stimulation (physical activity, environmental
enrichment), leading to appetite suppression and increased
energy expenditure [25, 30]. Downregulation of BDNF and
its receptor tropomyosin receptor kinase B (TrkB) in the
hypothalamus signiﬁcantly increases bodyweight and reduces
body temperature and locomotion in rodents [24, 44],
whereas the infusion of exogenous BDNF appears to reverse
this phenotype [24]. The relationship between whole-body
energy stores—particularly adiposity—and BDNF is less
consistent in humans, especially in children and youth.
In the current study, we did not observe any relationships
between adiposity and BDNF levels, which is consistent
with a recent sample of 447 healthy adolescents [45],
whereas other studies have reported BDNF levels that are
both lower [46] or higher [47] in youth with obesity com-
pared to those without. Interestingly, Roth et al. [47] observed
that changes in serum BDNF were signiﬁcantly correlated
with changes in adiposity and leptin following a one-year life-
style intervention targeting weight loss in adolescents with
obesity, which appears to be consistent with the relationships
found in animalmodels [30]. Collectively, these ﬁndings indi-
cate a complex and somewhat inconsistent relationship
between adiposity and resting BDNF in humans, particularly
in children, and therefore warrants future inquiry to clarify
these relationships in youth.
A major ﬁnding of this study was that exercise-induced
changes in serum BDNF were signiﬁcantly associated with
improvements in fasting glucose and HOMA-B, a measure
of pancreatic beta cell insulin secretion response to a glucose
load. From a clinical perspective, this is important given that
HOMA-B is one of the strongest risk/protective factors in the
development of T2D [48]. Although no directly comparable
studies exist in children, the few studies conducted can be
informative. Similar to our ﬁndings, Araya et al. [49] showed
that weight loss from caloric restriction increases serum
BDNF levels and improves glucose regulation in adults with
overweight and obesity; however, correlations between these
measures were not assessed. Conversely, Swift et al. [50]
failed to see any relationships between serum BDNF and glu-
cose control following a 9-month exercise intervention in
adults with T2D. Similarly, Roth et al. [47] showed that
changes in BDNF were not associated with HOMA-insulin
resistance; however, we are unable to compare these ﬁndings
Table 2: Relationship between changes in BDNF and changes in
anthropometrics and diabetes risk factors in the exercise group.
Measure Correlation, r p value
Δ weight −0.005 0.95
Δ waist circumference 0.02 0.81
Δ BMI 0.01 0.83
Δ %body fat −0.04 0.6
Δ glucose −0.17 0.04
Δ insulin 0.13 0.1
Δ HbA1c 0.01 0.89
Δ HOMA-B 0.23 0.005
Δ HOMA-IS −0.06 0.46
Note: BMI = body mass index; HbA1c = hemoglobin A1c; HOMA-B =
homeostatic model assessment beta cell secretory capacity; HOMA-IS =
homeostatic model assessment insulin sensitivity.
Table 3: Changes in diabetes risk factors predicting change in
BDNF in the exercise group.
Eﬀect Beta estimate SE p value
Change in glucose −6.565 3.374 0.054
Age −0.176 1.028 0.864
Gender 2.240 3.105 0.472
Highest parental education 0.444 1.856 0.811
Change in BMI 0.185 0.716 0.797
Change in HOMA-B 0.093 0.031 0.004
Age −0.551 1.031 0.594
Gender 3.802 3.129 0.226
Highest parental education 0.752 1.841 0.683
Change in BMI −0.652 0.766 0.396
Change in HOMA-IS −0.025 0.033 0.450
Age −0.592 1.069 0.581
Gender 3.206 3.247 0.325
Highest parental education 0.785 1.895 0.679
Change in BMI −0.133 0.787 0.866
Change in HbA1c (per 0.1%) 0.001 0.568 0.999
Age −0.238 1.035 0.818
Gender 2.563 3.143 0.416
Highest parental education 0.650 1.882 0.730
Change in BMI 0.173 0.750 0.818
Change in insulin 0.049 0.027 0.076
Age −0.643 1.048 0.540
Gender 3.478 3.209 0.280
Highest parental education 0.951 1.878 0.613
Change in BMI −0.358 0.773 0.644
Note: BMI = body mass index; HbA1c = hemoglobin A1c; HOMA-B =
homeostatic model assessment beta cell secretory capacity; HOMA-IS =
homeostatic model assessment insulin sensitivity.
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to the current study given that measures of HOMA-B and
HOMA-IS were not included. Rodent studies have estab-
lished the relationship between glucose regulation and
BDNF, and combined with some human models, these stud-
ies suggest the existence of a bidirectional relationship. Acute
hyperglycemia downregulates circulating plasma BDNF via
reduced output from the brain in healthy adults, and adults
with T2D appear to have lower resting BDNF levels, possibly
due to chronic hyperglycemia [22]. Conversely, both repeated
and single subcutaneous doses of exogenous BDNF rapidly
enhance insulin signaling [26] and lower blood glucose
through increases in glucose utilization [28] in the liver,
skeletal muscle, and brown adipose tissue of diabetic mice.
The hypoglycemic eﬀects of BDNF appear to be mediated
through the direct actions of BDNF on target tissue, as well
as its modulation of the central and peripheral nervous sys-
tems [28]. For example, overexpression of hypothalamic
BDNF stimulates the browning of white adipose tissue via
sympathetic nerve activity, leading to enhanced energy
expenditure and lowering of blood glucose via adaptive
thermogenesis [28, 29].
It is well established that acute exercise increases circulat-
ing BDNF [35] and may represent a “dose” of BDNF [31],
analogous to rodent infusion studies. For instance, 8 weeks
of treadmill training increases plasma BDNF in healthy rats
and BDNF appears to mediate the exercise-induced improve-
ments in insulin tolerance and increased beta cell size [14, 27].
Accordingly, exercise may improve diabetes risk factors and
obesity directly through its eﬀects on glucose regulation and
energy expenditure, as well as indirectly via its eﬀects on
BDNF and improvements in glucose regulation and meta-
bolic health from exercise. In turn, this may lead to increased
BDNF expression, thereby creating a synergistic feedback
loop. However, despite the wealth of plausible mechanisms,
it is important to note that the exercise-induced changes in
the outcome measures of the current study occurred at the
same time, thus preluding the determination of temporal
sequencing and causal inferences.
This study has limitations and strengths that warrant
mention. Strengths include the largest sample size of any ran-
domized controlled trial of supervised exercise in youth that
incorporated a broad scope of health indicators and a popu-
lation with obesity at high risk for both neurocognitive deﬁ-
cits and T2D. It is also the only exercise study in children
to include a measure of beta cell function, which led to a
novel ﬁnding that changes in beta cell function are associated
with changes in BDNF following a structured exercise inter-
vention. Limitations of the present study include a sample
that was primarily female, Caucasian, and primarily the oﬀ-
spring of well-educated parents; thus, results may not gener-
alize to youth coming from more diverse or disadvantaged
sociodemographic backgrounds. These ﬁndings may also
not be generalizable to children with developmental disabil-
ities, who are at an increased risk of obesity and metabolic
disorders [51]. Accordingly, future studies should investigate
the relationship between BDNF and metabolic outcomes fol-
lowing programmed exercise interventions in children with
developmental disabilities. Longer intervention duration
might have allowed a better quantiﬁcation of trajectories
and possible temporal sequencing of changes in BDNF and
diabetes risk factors, which should be explored in future
research. Future studies should also assess how changes in
quality of life and other indicators of psychosocial function-
ing relate to changes in BDNF and metabolic outcomes in
response to an exercise intervention in clinical populations,
such as adolescents with obesity. Lastly, although the current
study focused solely on the relationship between BDNF and
metabolic outcomes in response to exercise training, a note-
worthy limitation of this work is the lack of neurocognitive
assessment. Inclusion of these measures would provide a
more comprehensive understanding of the complex relation-
ships between BDNF, metabolic outcomes, and cognition in
response to exercise training in adolescents with obesity.
While these limitations cannot be overcome in the present
study, our data do provide a foundation to guide selection
and evaluation of outcomes for future exercise interventions
in the speciﬁc population studied, in order to gain a better
understanding of the potential neural eﬀects of exercise and
their relationship to changes in metabolic outcomes. Devel-
opmentally, such relationships seem to be less straightfor-
ward to predict than what could be conjectured based on
current animal and adult models.
In conclusion, our data show that exercise-induced
reductions in selected diabetes risk outcomes were associ-
ated with increases in resting serum BDNF levels in adoles-
cents with obesity. Given that BDNF plays a central role in
facilitating learning, memory, and neural plasticity [11],
combined with obesity representing potent risk factors for
both neurocognitive deﬁcits [3] and metabolic disorders
[10], our ﬁndings coupled with previous studies provide a
strong rationale for targeting BDNF signaling via exercise
interventions to treat the clustering of obesity, diabetes,
and neurological disorders.
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